Literature DB >> 31771642

Heat shock pretreatment improves mesenchymal stem cell viability by heat shock proteins and autophagy to prevent cisplatin-induced granulosa cell apoptosis.

Qing Wang, Xinran Li1, Qingru Wang1, Jiaxin Xie1, Chuhai Xie2, Xiafei Fu3.   

Abstract

BACKGROUND: Bone marrow mesenchymal stem cells (BMSCs) can partially repair chemotherapy-induced ovarian damage. However, low survival rate after transplantation hampers the therapeutic efficiency of BMSCs. Heat shock pretreatment (HSP) effectively improves the cell survival. This study attempted to investigate the mechanisms of HSP on BMSCs survival and the effects of heat shock-pretreated BMSCs (HS-MSCs) on cisplatin-induced granulosa cell (GC) apoptosis.
METHODS: BMSCs were isolated, cultured, and identified. After receiving HSP for different duration times in a 42 °C water bath, the apoptotic rates of BMSCs were detected by Annexin V-FITC/PI to determine the optimal condition of HSP. Cisplatin was added to the medium of HS-MSCs to simulate chemotherapy environment. The proliferative curve, apoptotic rate, and viability of HS-MSCs were determined by CCK-8, Annexin V-FITC/PI, and Hoechst33342/PI respectively to explore the alteration of biological characteristics. The levels of heat shock protein 70 and 90 (HSP70 and HSP90) and the expressions of autophagy-related markers (Beclin1 and LC3B) were detected by Western blot. In addition, the autophagosomes were observed by transmission electronic microscopy to discuss the possible mechanisms. The GCs were isolated, cultured, and identified. The HS-MSCs were co-cultured with GCs before and after the addition of cisplatin. Then, the apoptotic rate and viability of GCs were detected to investigate the therapeutic and preventive effects of HS-MSCs on GC apoptosis.
RESULTS: After receiving HSP at 42 °C for 1 h, BMSCs represented the lowest apoptotic rate. After the addition of cisplatin, the apoptotic rate of HS-MSCs (11.94% ± 0.63%) was lower than that of BMSCs (14.30% ± 0.80%) and the percentage of HS-MSCs expressing bright blue/dull red fluorescence was lower than that of BMSCs. The expression of HSP70 and HSP90 increased, while the number of autophagosomes, the expression of Beclin1, and the LC3BII/LC3BI ratio decreased in HS-MSCs. The apoptotic rates of GCs co-cultured with HS-MSCs before and after the addition of cisplatin were 39.88% ± 1.65% and 36.72% ± 0.96%, both lower than those of cisplatin-induced GCs (53.81% ± 1.89%).
CONCLUSION: HSP can alleviate the apoptosis and improve the survival of BMSCs under chemotherapy environment. The mechanism may be associated with the elevated expression of HSP70 and HSP90 and the attenuation of autophagy. Moreover, HS-MSCs have both therapeutic and preventive effects on cisplatin-induced GC apoptosis.

Entities:  

Keywords:  Apoptosis; Bone marrow mesenchymal stem cells; Cisplatin; Granulosa cells; Heat shock

Mesh:

Substances:

Year:  2019        PMID: 31771642      PMCID: PMC6880355          DOI: 10.1186/s13287-019-1425-4

Source DB:  PubMed          Journal:  Stem Cell Res Ther        ISSN: 1757-6512            Impact factor:   6.832


Background

Reproductive toxicity of chemotherapy agents is harmful to women who suffer from cancer. Severe ovarian damage induced by chemotherapy will cause great loss of follicles, resulting in premature ovarian insufficiency (POI). With improvement in the long-term survival rates of children and young adults who have cancer, increasing importance has been attached to the treatment of the damaged ovary [1, 2]. However, there is no effective measure for chemotherapy-induced POI. Therefore, new treatment strategies are urgently needed. Recently, regenerative medicine researches have shown that mesenchymal stem cell (MSC) transplantation can restore the function of damaged tissues, which provides a potential therapy on chemotherapy-induced POI [3]. However, BMSC transplantation did not attain the expected repair effect. The hampered ovarian therapeutic efficiency of BMSCs may be attributed to the low survival rate after transplantation. In addition, BMSCs apoptosis and necrosis mainly occurred within 4 days after transplantation [4]. Hence, finding new strategies in an attempt to overcome this obstacle is the key to improve the curative effect of BMSCs in chemotherapy-induced POI. Heat shock pretreatment (HSP) is an effective way to protect cells before and after transplantation. Recent studies have been shown that HSP does enhance the survival rate and reduce the apoptotic rate of transplanted MSCs [5, 6]. Our previous study demonstrated that HSP can ameliorate the therapeutic effect of BMSCs on a chemotherapy-induced POI rat model [7]. However, whether HSP inhibits BMSCs apoptosis to protect the granulosa cells (GCs) against cisplatin is still unknown. This study is to investigate the protective effects and the related mechanisms of HSP on BMSCs apoptosis. Additionally, the therapeutic effect of HS-MSCs on protecting GCs against cisplatin is also detected. Firstly, four HSP duration times were set up and the optimal condition was obtained by detecting BMSCs apoptosis. Secondly, cisplatin was added to HS-MSCs medium to mimic the in vivo microenvironment of chemotherapy. The proliferation, apoptosis, and viability of HS-MSCs were further detected to determine the changes of biological characteristics. Then, the levels of autophagy and heat shock proteins were detected to discuss the related mechanism in the improvement of the repair effect in HS-MSCs. Finally, GCs were isolated and cisplatin was added to the GCs medium to establish the in vitro model of chemotherapy-induced POI. The HS-MSCs were co-cultured with GCs before and after cisplatin addition to evaluate the preventive and therapeutic effects of HS-MSCs on the cisplatin-induced GCs apoptosis.

Methods

Animals

Female Wistar rats (80–100 g; 4–5 weeks old) from the Laboratory Animal Center of Southern Medical University were used in this study. The rats were maintained under laboratory conditions with controlled temperature (23 ± 2 °C), humidity 45–55%, 12:12-h light-dark cycle, and free access to standard diet and sterile water. The rats were under pentobarbital sodium anesthesia and then euthanized for sampling. This study was conducted in compliance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health [8]. All study procedures were approved by the Committee on the Ethics of Animal Experiments of Southern Medical University (Permit Number: L2016039).

Isolation, culture, and identification of BMSCs

Rats were anesthetized with pentobarbital sodium and euthanized. Bilateral femurs and tibiae were harvested and flushed with complete culture medium containing 10% FBS. Following centrifugation at 2500 rpm for 20 min with Percoll at a density of 1.073 g/mL, mononuclear cells at the interface were collected. Cells were washed twice with PBS then were resuspended in DMEM/F12 complete medium containing 10% FBS supplemented with 100 U/mL penicillin and 0.1 mg/mL streptomycin. The resulting cell suspension (1 × 106 cells/mL) was inoculated into a culture plate, which was incubated at 37 °C with 95% humidity and 5% CO2. Non-adherent cells were removed after 72 h and then the fresh culture medium was replaced. BMSCs were identified by flow cytometry to detect the cells that expressed the typical surface markers CD44, CD45, CD29, and CD34. Passage was performed in a 1:2 proportion after cells reached the 80% confluence. The third passage of BMSCs in good growth status was separated for the preparation of single cell suspension then used for the following experiments.

Isolation and culture of GCs

Rats received subcutaneous injection of pregnant mare serum gonadotropin (PMSG) (100 IU per rat) 48 h before being sacrificed. Bilateral ovaries were aseptically harvested within 20 min of slaughter and rinsed in petri dishes containing chilled PBS, supplemented with 100 U/mL penicillin and 0.1 mg/mL streptomycin. Afterward, the ovaries were separated from the oviducts, bursa, and fat under a stereomicroscope and then were transported to DMEM/F12 supplemented with 10% FBS, 100 U/mL penicillin, and 0.1 mg/mL streptomycin. Mature follicles were pricked with 1-mL syringe needles to extrude GCs. Cell suspension was filtered through a 70-μm filter and centrifuged at 1000 rpm for 10 min at 4 °C, and the supernatant had been carefully removed. Finally, GCs were resuspended after washing twice in PBS and were cultured at 37 °C and 95% humidity with 5% CO2 in the incubator. Presence or absence of cell attachment was observed and confirmed 48 h after incubation. The medium was replaced to remove unattached cells, and this procedure was repeated every 72 h.

Identification of GCs

HE staining

Cell crawling slides were collected and fixed in 4% paraformaldehyde for 20 min. Then, they were washed with PBS three times for 5 min each time. Cell slides were stained with hematoxylin for 3 min, differentiated with hydrochloric ethanol for 15 s, and stained with blue buffer for 15 s. Cell slides were subsequently stained with eosin for 3 min and rinsed with running water. Lastly, they were conventionally dehydrated with an ethanol and xylene gradient, mounted in neutral resin, and observed under a microscope.

FSHR immunocytochemistry

Cells were fixed in 4% paraformaldehyde for 15 min and washed with PBS three times for 3 min each time. Cells were then incubated in a 3% hydrogen peroxide solution (H2O2) at room temperature for 10 min to inactivate endogenous peroxidase and washed with PBS three times for 5 min each time. Subsequently, 5% BSA was added to the petri dish and cells were blocked at room temperature for 30 min. The primary antibody rabbit polyclonal FSHR (1:500, bs-20658R, Bioss) was added dropwise and incubated in wet box overnight at 4 °C. Goat anti-rabbit IgG secondary antibody marked by horseradish peroxidase (HRP) (1:500, SV0002, Boster) was added dropwise, and the cells were incubated at room temperature for 30 min. Diaminobenzidine tetrahydrochloride (DAB) was added as a substrate and stained for 5–10 min. Next, cells were flushed fully with running water and counterstained with hematoxylin for 3 min. Finally, cells were conventionally dehydrated with an ethanol and xylene gradient and mounted in neutral resin. Immunoreactivity was detected using a fluorescence microscope.

Confirming the optimal condition of HSP

The third passage of BMSCs was harvested and pre-cultured as previously described. Cells were divided into five parallel groups, namely, the normal group, 30 min group, 1 h group, 2 h group, and 3 h group; each group had four samples. For the normal group, BMSCs were cultured under normal condition without HSP. For the other four groups, BMSCs received HSP in a 42 °C water bath for four time durations (30 min, 1 h, 2 h, and 3 h, respectively). After replacing the fresh medium, BMSCs in all groups were incubated at 37 °C with 5% CO2 for 24 h, 48 h, and 72 h. The apoptotic rates of BMSCs at different time points were detected with Annexin-V/PI.

Detecting the effect of HSP on biological characteristics of cisplatin-induced BMSCs

BMSCs were divided into four groups, namely, the blank control group, HS-MSC group, model group, and HS-MSC model group. The blank control group was cultured under normal conditions without HSP. The HS-MSC group received HSP under the optimal condition. The model group was co-cultured with 5 mg/L cisplatin for 48 h without HSP. The HS-MSC model group received HSP under the optimal condition, and 5 mg/L cisplatin was added to the medium of HS-MSCs for 48 h. BMSCs in all groups were incubated at 37 °C, with 5% CO2. The cell proliferative curve was determined by CCK-8 assay. In addition, the cell apoptotic rate and viability were respectively detected by Annexin V/PI double staining using flow cytometery and were valued by Hoechst 33342/PI double staining under a fluorescence microscope.

CCK-8 assay

Cell proliferation rate was determined using Cell Counting Kit-8 (KGA317, Keygenbio). For each group, BMSCs were inoculated into five wells of the 96-well plates (2 × 103 cells per well). When cells began to adhere, the model group and HS-MSC model group were added with proper concentration of cisplatin (5 mg/L) for 48 h. BMSCs of each group were harvested and incubated with 10 μL CCK-8 reagents at room temperature with 5% CO2 for 4 h. The absorbance at 490 nm was then measured by using an automatic microplate reader for 7 days consecutively.

Annexin-V/PI double staining assay

After receiving HSP under the optimal condition and incubating for 72 h, BMSCs were washed with PBS three times and collected. Annexin V-FITC/PI double staining assay was performed by utilizing the Annexin V-FITC/PI Apoptosis Kit (AP101-100-kit, MULTI SCIENCES) according to the manufacturer’s instructions. Briefly, 195 μL binding buffer and 5 μL Annexin V-FITC were added and incubated at room temperature away from light for 10 min. Next, 200 μL binding buffer that contained 10 μL PI was added and incubated at room temperature away from light for 15 min. The samples were immediately analyzed using FACS (Becton, Dickinson and Company, Franklin Lake, NJ, USA). The equation (number of cells in the upper right quadrant + cells in the lower right quadrant) / (total cell number) was used to calculate the apoptotic rate.

Hoechst33342/PI double staining assay

BMSCs of each group were harvested and fixed in 4% paraformaldehyde for 15 min. Then, the fixative solution was discarded and BMSCs were washed with PBS three times for 3 min each time. Next, Hoechst 33342 was added and cells were stained away from light at room temperature for 5 min. The staining solution was removed and cells were washed with PBS three times for 3 min each time. PI staining solution was then added and incubated at 4 °C for 30 min. The staining solution was removed and BMSCs were washed with PBS three times for 3 min each time. Finally, the redundant liquid was discarded and the slides of cells were covered with anti-quenching mounting medium. BMSCs were observed under a fluorescence microscope.

Exploring the related mechanisms of HSP in BMSCs survival

Heat shock protein 70 and 90 levels

Cells were incubated at 37 °C and 5% CO2 for 0 h, 2 h, 24 h, 48 h, 72 h, 96 h, and 120 h and harvested at different time points to detect heat shock protein 70 (HSP70) and heat shock protein 90 (HSP90) levels by Western blot. Briefly, for preparation of total cell lysates, cells were washed twice with chilled PBS and lysed with lysis solution. The protein concentration was equalized using a bicinchoninic acid (BCA) protein assay kit (Pierce; 23227) according to the manufacturer’s instructions. Protein lysates were denatured at 100 °C for 5 min. The protein fractions were resolved by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transblotted onto polyvinylidene fluoride (PVDF) membranes (Millipore, Bedford, MA, USA). After blocking with 5% nonfat dry milk in TBST (Tris-buffered saline containing 50 mM Tris/HCl, pH 8.8, 125 mM NaCl, and 0.05% Tween-20), membranes were incubated with primer antibodies including mouse monoclonal anti-HSP70 (ab47455, Abcam, 1:1000) and mouse monoclonal anti-HSP90 beta (ab53497, Abcam, 1:2500) overnight at 4 °C. After incubation with secondary antibody peroxidase-conjugated goat anti-mouse IgG (H+L) (ZB-2305, ZSGB-BIO, 1:2000) at room temperature for 26 min, immunoreactivity was visualized using an ECL kit (Perkin-Elmer Life Science, Fremont, CA, USA). Protein bands were normalized by mouse monoclonal anti-β-actin (TA-09, ZSGB-BIO, 1:2000) and analyzed with an Image 16.7 (NIH USA) software. All steps were repeated in triplicate.

Autophagy-related markers Beclin1 and LC3B

BMSCs were randomly divided into six groups, namely, the blank control group, HS-MSC group, model group, HS-MSC model group, rapamycin group, and 3-MA group. The blank control group was cultured under normal conditions without cisplatin and HSP. The HS-MSC group received HSP under the optimal condition without cisplatin. The model group was co-cultured with 5 mg/L cisplatin for 48 h without HSP. The HS-MSC model group was received HSP under optimal condition and subsequently co-cultured with 5 mg/L cisplatin for 48 h. The rapamycin group and 3-MA group both received HSP under optimal condition and co-cultured with 5 mg/L cisplatin. Then, the rapamycin group was co-cultured with autophagy promoter rapamycin (10 nM; HY-10219; MCE), and the 3-MA group was co-cultured with autophagy inhibitor 3-methyladenine (3-MA; 5 mM; HY-19312; MCE). The total contact time between GCs and cisplatin in both the rapamycin and 3-MA groups was 48 h. RIPA lysates from all groups were collected and protein concentrations were quantified using the BCA protein assay. Equal amounts of protein were separated by 12% SDS-PAGE and transferred to PVDF membranes and then were analyzed by electrophoresis. Membranes were incubated with primary antibody against rabbit monoclonal anti-Beclin1 (ab207612, Abcam, 1:2000), rabbit monoclonal anti-LC3B (ab192890, Abcam, 1:2000), or mouse monoclonal anti-β-actin (TA-09, ZSGB-BIO, 1:2000) overnight at 4 °C and were then incubated with a secondary antibody peroxidase-conjugated goat anti-mouse IgG (H+L) (ZB-2305, ZSGB-BIO, 1:2000) at room temperature for 1 h. Finally, protein levels were detected using the ECL light system (Perkin-Elmer Life Science, Fremont, CA, USA). Pictures were analyzed using the Image 16.7 (NIH USA) software. The band intensity was normalized to that of β-actin. All steps were repeated in triplicate.

Autophagosome observation

BMSCs in the blank control group, HS-MSC group, model group, HS-MSC model group, rapamycin group, and 3-MA group were fixed in 2.5% glutaraldehyde, followed by post fixation in 2% osmium tetroxide, dehydration in ascending series of ethanol, and embedding in epoxy resin (SPI Inc., Westchester, PA). Ultrathin sections (60 nm) were stained with uranyl acetate and lead citrate and then examined with a transmission electron microscope (Hitachi; H-7500). Autophagosome morphology and quantification of autophagic accumulation were observed according to the previous description [9].

Determining the effect of HS-MSCs on cisplatin-induced GCs apoptosis

GCs were isolated, cultured, and identified as above and were randomly divided into six groups, namely, the normal group, model group, MSC prevention group, HS-MSC prevention group, MSC treatment group, and HS-MSC treatment group. The normal group was cultured under normal conditions without cisplatin and HSP. The model group was co-cultured with 5 mg/L cisplatin for 48 h without HSP. GCs of the MSC prevention group and HS-MSC prevention group were respectively co-cultured with BMSCs and heat shock-pretreated BMSCs (HS-MSCs) according to the ratio of 1:1 for 24 h. Subsequently, two groups were both co-cultured with 5 mg/L cisplatin for 48 h. GCs of the MSC treatment group and HS-MSC treatment group were firstly co-cultured with 5 mg/L cisplatin for 24 h to induce GC apoptosis. Then, two groups were respectively co-cultured with BMSCs and HS-MSCs according to the ratio of 1:1 for 24 h. The total contact time between GCs and cisplatin in all groups was 48 h. The apoptotic rates of GCs were detected by Annexin-V/PI double staining using flow cytometry and were valued by Hoechst33342/PI double staining under a fluorescence microscope.

Statistics analysis

All values are presented as mean ± SD and were analyzed by one-way analysis of variance (ANOVA) and SNK test with SPSS 22.0 (SPSS, Inc., Chicago, IL) for Windows. ANOVA followed by post hoc Dunnett test was used to determine statistical differences between groups, and the SNK test was used to evaluate the difference between two groups. P < 0.05 was considered significantly different.

Results

Culture and identification of BMSCs

Cell morphology of the third passage BMSCs presented a fibroblast-like morphology, became uniform as a fusiform shape, and were arranged regularly (Fig. 1a). Flow cytometry indicated that over 90% of BMSCs were positive for CD44 and CD29, while they were negative for CD34 and CD45 (Additional file 1: Figure S1). Consistent with the previous study, our result confirmed that the cultured cells were BMSCs with classical MSC phenotype rather than hematopoietic stem cells.
Fig. 1

Morphological observation of rat BMSCs and GCs. a The third generation of BMSCs at the third day (× 100). b GCs cultured in vitro for 3 days (original magnification, × 400). Identification of GCs (c, d). c HE staining for identification of the cells (× 400). d Immunocytochemical staining for FSHR for identification of the GCs (× 400)

Morphological observation of rat BMSCs and GCs. a The third generation of BMSCs at the third day (× 100). b GCs cultured in vitro for 3 days (original magnification, × 400). Identification of GCs (c, d). c HE staining for identification of the cells (× 400). d Immunocytochemical staining for FSHR for identification of the GCs (× 400)

Isolation, culture, and identification of GCs

GCs attached to the culture plate completely within 2–3 days of incubation and displayed monolayer growth, extended, and became colony-like. As evident from the light microscope photographs, GCs presented a fusiform shape and the cytoplasmic granules were observed (Fig. 1b). HE staining showed that adherent GCs were seen to be polygonal, have a round nucleus, and have a large and deep-dyed pink cytoplasma full of granules and vacuoles (Fig. 1c). In addition, FSHR immunocytochemistry staining demonstrated that over 95% of cells were FSHR positive, characterized by the brown-stained cytoplasma and blue-dyed nucleus (Fig. 1d).

Optimal conditions of HSP

After receiving HSP under different conditions (42 °C for 0 min, 30 min, 1 h, 2 h, 3 h), BMSCs were harvested at 24 h, 48 h, and 72 h to detect apoptotic rate by flow cytometry. There were significant differences in one-way ANOVA among groups (F24 h = 29.408, P24 h = 0.000; F48 h = 39.206, P48 h = 0.000; F72 h = 4.884, P72 h = 0.010). At three time points, BMSCs of the 1 h group had the lowest apoptotic rates among all groups. At 24 h after HSP, the apoptotic rates of the normal group, 30 min group, 1 h group, 2 h group, and 3 h group were 5.88% ± 1.80%, 4.67% ± 1.91%, 3.93% ± 1.11%, 14.58% ± 3.42%, and 19.61% ± 3.66%, respectively. At 48 h and 72 h after HSP, the apoptotic rates of all groups were significantly decreased than that at 24 h (Fig. 2a–f). Therefore, the optimal HSP condition was determined (42 °C for 1 h) and used in the subsequent experiments.
Fig. 2

Confirmation of the optimal condition of HSP. Apoptosis of BMSCs at 48 h after HSP detected by Annexin V/PI using flow cytometry. a Normal group. b 30 min group. c 1 h group. d 2 h group. e 3 h group. f Apoptosis of BMSCs at 24 h, 48 h, and 72 h after HSP. *P < 0.05 vs normal group

Confirmation of the optimal condition of HSP. Apoptosis of BMSCs at 48 h after HSP detected by Annexin V/PI using flow cytometry. a Normal group. b 30 min group. c 1 h group. d 2 h group. e 3 h group. f Apoptosis of BMSCs at 24 h, 48 h, and 72 h after HSP. *P < 0.05 vs normal group

Alteration of biological characteristics in HS-MSCs

The absorbance value (OD value) of BMSCs of the blank control group, HS-MSC group, model group, and HS-MSC model group was detected by CCK-8 assay to determine the proliferative capacity. The cell growth curve was plotted according to the average value of each pore. Cell proliferation of the HS-MSC group was increased at 2 and 3 days after HSP (td2 = 29.198, Pd2 = 0.000; td3 = 33.686, Pd3 = 0.000), demonstrating that HSP has a positive effect on the proliferation of BMSCs. Additionally, the proliferation rate of HS-MSCs rose rapidly before 72 h and then reached a plateau (Fig. 3a).
Fig. 3

The alteration of biological characteristics in BMSCs after HSP. a The growth curve of four groups. #P < 0.05 vs blank control group; *P < 0.05 vs model group. The apoptosis and viability of BMSCs were observed in four groups (b–d). b, c Cell apoptosis rate of the BMSCs with different treatments detected by Annexin V-FITC/PI using flow cytometry. **P < 0.01 vs blank control group. *P < 0.05 vs model group. d Detection of cell viability by Hoechst33342/PI staining (original magnification, × 40)

The alteration of biological characteristics in BMSCs after HSP. a The growth curve of four groups. #P < 0.05 vs blank control group; *P < 0.05 vs model group. The apoptosis and viability of BMSCs were observed in four groups (b–d). b, c Cell apoptosis rate of the BMSCs with different treatments detected by Annexin V-FITC/PI using flow cytometry. **P < 0.01 vs blank control group. *P < 0.05 vs model group. d Detection of cell viability by Hoechst33342/PI staining (original magnification, × 40) The apoptosis of BMSCs was measured by Annexin V-FITC/PI double staining using flow cytometry. At 72 h after HSP, the apoptotic rates of the blank control group, HS-MSC group, model group, and HS-MSC model group were 8.08% ± 0.44%, 4.62% ± 0.08%, 14.30% ± 0.80%, and 11.94% ± 0.63%, respectively. Results revealed that the apoptotic rate of the HS-MSCs group was significantly lower than that of the blank control group (P < 0.01). Meanwhile, the apoptotic rate of the HS-MSC model group was significantly lower than that of the model group (P < 0.05) (Fig. 3b, c). The viability of BMSCs was detected by Hoechst33342/PI double staining assay and observed under a fluorescence microscope. Following staining with Hoechst33342/PI, apoptosis is identified by bright blue fluorescence because of the high permeability of cell membranes. Moreover, necrotic cells represent red fluorescence due to the penetration of PI, and viable cells show dull blue and dull red fluorescence. The proportion of BMSCs presenting bright blue/dull red fluorescence in the HS-MSC group was significantly lower than that in the blank control group, indicating the decreased apoptosis of HS-MSCs. Additionally, the percentage of BMSCs presenting bright blue/dull red fluorescence in the HS-MSC model group was significantly lower than that in the model group. The results described above were consistent with those of flow cytometry (Fig. 3d).

HSP70 and HSP90 expressions in HS-MSCs

Results showed that HSP70 and HSP90 both had elevated expressions in HS-MSCs, which increased significantly from 2 h and maintained high expression until 96 h (P < 0.01). After reaching the peak at 48 h, expressions of HSP70 and HSP 90 then gradually decreased to about 0 h levels at 120 h, but the differences of HSP70 and HSP90 between 0 h and 120 h were not statistically significant (P > 0.05) (Fig. 4a, b). These results suggested that the highest expression of HSP70 and HSP90 is at 48 h after receiving HSP under optimal condition (42 °C, 1 h). Thus, HS-MSCs cultured for 48 h after HSP (42 °C, 1 h) were used for subsequent experiments.
Fig. 4

Expressions of heat shock proteins and autophagy-related markers in HS-MSCs. a Western blot analysis was performed to detect HSP70 and HSP90 at different time points. b Densitometry for HSP70 and HSP90 after normalization against actin levels. The data shown are the average of three independent experiments with error bars denoting SD. *P < 0.05 for significant differences between 0 h. c Western blot analysis was performed to detect Beclin1 and LC3B. d Densitometry for Beclin1 and LC3B after normalization against actin levels. *P < 0.05 vs model group

Expressions of heat shock proteins and autophagy-related markers in HS-MSCs. a Western blot analysis was performed to detect HSP70 and HSP90 at different time points. b Densitometry for HSP70 and HSP90 after normalization against actin levels. The data shown are the average of three independent experiments with error bars denoting SD. *P < 0.05 for significant differences between 0 h. c Western blot analysis was performed to detect Beclin1 and LC3B. d Densitometry for Beclin1 and LC3B after normalization against actin levels. *P < 0.05 vs model group

Autophagy-related markers Beclin1 and LC3B expressions after HSP

To detect whether HSP induced autophagy in HS-MSCs, we examined protein levels of key autophagy-related markers Beclin1 and LC3B. As shown in Fig. 4c, d, the Beclin1 protein levels (166.79 ± 12.44) and the ratio of LC3BII/LC3BI (0.47 ± 0.08) in the HS-MSC group were both significantly decreased compared with those in the blank control group (260.81 ± 23.66 and 1.22 ± 0.07) (P < 0.05), indicating that HSP can effectively reduce the autophagy levels. In addition, the Beclin1 protein levels (1111.58 ± 12.13) and the ratio of LC3BII/LC3BI (1.89 ± 0.02) in the model group were both significantly increased compared with those in the blank control group (P < 0.05), which indicated that autophagy is activated in BMSCs co-cultured with cisplatin. Meanwhile, the Beclin1 protein levels (522.49 ± 17.90) and the ratio of LC3BII/LC3BI (1.58 ± 0.05) in the HS-MSC model group were both significantly decreased compared with those in the model group (P < 0.05). Following 3-MA treatment, attenuated activation of autophagy was detected in the 3-MA group compared with the HS-MSC model group, as shown by the lower expression level of Beclin1 (334.68 ± 17.32) and lower ratio of LC3BII/LC3BI (0.98 ± 0.05) (P < 0.05). However, after treating with rapamycin, a higher expression level of Beclin1 (1528.66 ± 23.61) and ratio of LC3BII/LC3BI (1.66 ± 0.02) was found in the rapamycin group than in the HS-MSC model group (P < 0.05). These results revealed that the alleviation of autophagy by HSP may serve as a protective mechanism against apoptosis in BMSCs exposed to cisplatin.

The number of autophagosomes after HSP

The number of autophagosomes in the blank control group, model group, HS-MSC group, HS-MSC model group, 3-MA group, and rapamycin group was observed by transmission electron microscopy (TEM). Representative electron micrographs demonstrated that the number of autophagosomes in the model group was increased compared with that in the blank control group (P < 0.05). On the contrary, after receiving HSP, the number of autophagosomes in the HS-MSC group was decreased compared with that in the blank control group. Meanwhile, the number of autophagosomes in the HS-MSC model group was decreased compared with that in the model group (P < 0.05). Additionally, the number of autophagosomes in the rapamycin group was increased compared with that in the 3-MA group (P < 0.05). These results were in line with the autophagy levels detected by Western blot (Fig. 5).
Fig. 5

The number of autophagosomes in each group was observed by TEM. Representative electron micrographs demonstrated autophagic vacuole formation in each group. The red arrows indicate the double-membrane vacuoles digesting organelles or cytosolic contents

The number of autophagosomes in each group was observed by TEM. Representative electron micrographs demonstrated autophagic vacuole formation in each group. The red arrows indicate the double-membrane vacuoles digesting organelles or cytosolic contents

The effects of HS-MSCs on cisplatin-induced GC apoptosis

Flow cytometry showed that the apoptotic rates of GCs in the normal group, model group, MSC prevention group, HS-MSC prevention group, MSC treatment group, and HS-MSC treatment group were 31.13% ± 2.81%, 53.81% ± 1.89%, 50.21% ± 1.68%, 39.88% ± 1.65%, 42.76% ± 0.99%, and 36.72% ± 0.96%, respectively. Statistical analysis revealed significant differences in the apoptotic rate among the six groups (F = 127.6, P = 0.000). The apoptotic rates of the HS-MSC prevention group and HS-MSC treatment group were both significantly lower than that of the model group (P < 0.05). However, no significant difference was observed between the HS-MSC prevention and treatment groups (P > 0.05). These results indicated that HS-MSCs play a key role in preventive and therapeutic effects on apoptosis of GCs, but there was no significant difference between the two effects (Fig. 6a, b).
Fig. 6

The apoptosis and viability of GCs in each group. a, b Cell apoptosis of the GCs with different treatments detected by Annexin/V using flow cytometry. *P < 0.05 vs model group. c Detection of cell viability by Hoechst33342/PI staining (original magnification, × 40)

The apoptosis and viability of GCs in each group. a, b Cell apoptosis of the GCs with different treatments detected by Annexin/V using flow cytometry. *P < 0.05 vs model group. c Detection of cell viability by Hoechst33342/PI staining (original magnification, × 40) For Hoechst33342/PI double staining, the proportion of GCs presenting bright blue/dull red fluorescence in the HS-MSC treatment group was significantly lower than that of the MSC treatment group, indicating that HS-MSCs have a stronger therapeutic effect than BMSCs on cisplatin-induced GC apoptosis. Moreover, the proportion of GCs presenting bright blue/dull red fluorescence in the HS-MSC prevention group was significantly lower than that in the MSC prevention group, revealing that GCs co-cultured with HS-MSCs before adding cisplatin have a stronger preventive effect on GC apoptosis. These results were consistent with those of flow cytometry (Fig. 6c).

Discussion

Current clinical treatments of chemotherapy-induced POI include hormone therapy, oocyte/ovarian cryopreservation, in vitro oocyte activation and maturation, and IVF-ET [10]. These treatments still remain limited, and none of them can efficaciously cure chemotherapy-induced POI. Mesenchymal stem cells (MSCs) are non-specialized cells which have vast application prospectively in regenerative therapy owing to the ability of self-renewal and multiple differentiative potentials. So far, there are 16 clinical trials of stem cell therapy for POI worldwide registered in the system according to the search results of the Clinical Trials Register website (clinicaltrials.gov). It has been reported that MSCs can repair ovarian damage to some extent and partly improve the ovarian endocrine function [11]. Our previous research has shown that BMSC transplantation can effectively inhibit GC apoptosis and partially recover ovarian damage induced by the application of chemotherapy agents in vivo [7], but the therapeutic effect is not up to the expectation. Cell loss after transplantation is the main cause of attenuated therapeutic efficiency. Thus, improving the viability of BMSCs in ovarian tissue is essential for enhancing its long-term efficacy. Heat shock pretreatment (HSP) is an effective way to improve the viability, proliferative capacity, and anti-apoptosis ability of MSCs [6, 12, 13]. Murry [14] found that MSCs receiving HSP before transplantation can reduce apoptosis by about 54% in rat models of myocardial injury. Feng [15] has reported that short-term HSP can significantly inhibit the apoptosis of transplanted Sca-1+ stem cells and thus enhance their effect on reducing myocardial fibrosis and improving cardiac function in a myocardial infarction rat model. Furthermore, Peng [16] demonstrated that HSP can effectively reduce apoptotic rates of MSCs and the transplantation of HS-MSCs resulted in decreased serum amino transferase levels and improved histopathology in a hepatic ischemia-reperfusion injury rabbit model. However, whether HSP can promote the effect of BMSCs in premature ovarian insufficiency (POI) is not clear. Therefore, we perform this study to investigate the effect and mechanisms of HSP on BMSCs survival and to identify the key role of heat shock-pretreated BMSCs (HS-MSCs) in preventing cisplatin-induced granulosa cells (GCs) apoptosis. The condition of HSP differed greatly according to different types of cells. In this study, we found that the apoptotic rate of BMSCs was significantly decreased after HSP at 42 °C for 1 h, and so it was determined to be the optimal condition of HSP. We further investigated the biological characteristic changes of BMSCs after HSP. Results suggested that HSP significantly improved the proliferative capacity, viability, and anti-apoptosis ability of BMSCs, indicating that HSP is an effective method to improve the survival rate and enhance the tissue repair capability of transplanted BMSCs. Furthermore, an in vitro model of GCs apoptosis induced by cisplatin was established to explore whether HS-MSCs have a stronger effect than BMSCs in preventing or reducing GCs apoptosis. Results indicated the preventive and therapeutic effects of HS-MSCs in cisplatin-induced GCs apoptosis, but there was no significant difference between the two effects. At present, the specific mechanisms of HSP in improving the viability and inhibiting the apoptosis of BMSCs still remain unknown. It is widely believed that heat shock proteins are closely related to the inhibition of apoptosis by HSP [17]. Highly expressed heat shock proteins provide a period of heat tolerance for cells and provide temporary resistance to subsequent stress stimulation. Studies have shown that MSCs treated with moderate heat shock can enhance their viability and proliferation and decrease apoptosis. Choudhery [6] found elevated heat shock proteins 27, 70, and 90; decreased apoptotic cells; and increased proliferated MSCs after HSP. Park [18] also found that HSP may increase the expression of heat shock proteins 60, 70, and 90 by up-regulating heat shock factor 1 (HSF1), enhancing the proliferation and survival of target cells. Feng [15] found that HSP may up-regulate HSF1 and activate the HSF1/miR-34a/HSP70 pathway, therefore leading to the reduction of the apoptosis of Sca-1+ stem cells and myocardial fibrosis and the improvement of cardiac function. Therefore, we consider that the increase of anti-apoptotic ability of MSCs may be related to the increase of heat shock proteins. In order to explore the correlation between the anti-apoptosis ability of HS-MSCs and heat shock proteins, Western blot was performed to detect the expression of HSP70 and HSP90. We found the constantly elevated protein levels of HSP70 and HSP90 in BMSCs after receiving HSP under optimal condition (42 °C, 1 h), which were sustained in an extended period of time. In addition, the protein levels of HSP70 and HSP90 reached peak at 48 h after HSP and were restored to about 0 h level at 120 h. It is suggested that the increased HSP70 and HSP90 levels might be closely related to the decreased apoptosis of HS-MSCs, which was consistent with the result of a previous study [13]. A recent study has reported that HSP90 activates signal transducer and activator of transcription 3 (STAT3) in stem cells by forming the HSP90/Hop complex [19], which regulates self-renewal and differentiation of stem cells [20]. Moreover, the anti-apoptosis effect of heat shock proteins has been confirmed, exerted by blocking the multiple apoptotic pathways. HSP90 blocks the intrinsic apoptotic pathway through binding the caspase-recruitment domain of apoptotic protease-activating factor-1 (Apaf-1), thereby inhibiting the formation of a functional apoptosome [21]. In addition, other studies have also shown that HSP70 inhibits apoptosis by binding caspase-independent death effector apoptosis-inducing factor (AIF), thereby preventing caspase-independent processes [22]. Meanwhile, HSP70 and HSP90 are important for binding and stabilizing unfolded proteins and favor their folding in stress condition [23], which enhance cell survival. Therefore, a high expression of heat shock proteins, especially HSP70 and HSP90, could promote the self-renewal and differentiation of stem cells, thereby playing a key role in cell survival, apoptosis, and the aging process. Autophagy might be another mechanism involved in the anti-apoptosis effect [23]. Gordon PB [23] first found the effect of temperature elevation on autophagy induction of rat hepatocytes in vitro. The highest autophagy level was presented at 37 °C, while the lowest autophagy level was presented at 40 °C. Peng [16] found that heat shock could induce autophagy of BMSCs after exposure to H2O2. Herberg [24] also reported that heat shock may activate autophagy through the SDF-1/CXCR4 axis and play a key role in mediating the survival of MSCs exposed to H2O2. Numerous data indicated that autophagy acts as either a protagonist or an antagonist of apoptosis, and its effect mainly depends on the category of cell and the difference of condition [25]. In the present study, we found that chemotherapy microenvironment can activate autophagy. Moreover, the number of autophagosomes and the levels of autophagy-related markers in BMSCs were significantly decreased after receiving HSP, indicating that HSP inhibits the activation of autophagy in HS-MSCs. A recent study has found that overexpression of heat shock factor 1 (HSF1) could suppress the basal level of LC3-II protein and inhibit the activation of autophagy after heat treatment [26]. On the contrary, the loss of HSF1 could increase the basal level of autophagy [27]. These results implicated the vital role of active HSF1 in regulating autophagy in heat shock response. Additionally, mitogen-activated protein kinase (p38MAPK) is a positive regulator of autophagy and is regulated by HSP to improve cardiac cell survival [28]. p38MAPK can be activated in response to exogenous stress such as hypoxia, starvation, and heat shock, which in turn activates mitogen-activated protein kinase kinases (MKK)-3/4/6 and their effector kinases to stimulate autophagy. However, little is known about the function of the p38MAPK pathway in regulating the activation of autophagy in MSCs following HSP. Moreover, autophagy can also directly promote type II programmed cell death [29]. Overall, the potential mechanism of autophagy in regulating the heat shock has not been fully elucidated and further study is needed.

Conclusions

In summary, our findings confirmed the optimal condition of HSP and indicated that HSP effectively improves the proliferative capacity, viability, and anti-apoptosis ability of BMSCs under chemotherapy environment. In addition, the elevated expressions of HSP70 and HSP90 and attenuation of autophagy may be involved in the mechanisms of HSP in preventing apoptosis and improve survival of BMSCs. Finally, HS-MSCs have both preventive and therapeutic effects on cisplatin-induced GCs apoptosis. Additional file 1: Figure S1. Identification of the surface markers of MSCs. a: MSCs are positively expressed surface markers CD29 and CD44; b: MSCs are positively expressed surface markers CD34 and CD45.
  28 in total

1.  Cardiomyocyte grafting for cardiac repair: graft cell death and anti-death strategies.

Authors:  M Zhang; D Methot; V Poppa; Y Fujio; K Walsh; C E Murry
Journal:  J Mol Cell Cardiol       Date:  2001-05       Impact factor: 5.000

2.  Kinetics of thermally induced heat shock protein 27 and 70 expression by bone marrow-derived mesenchymal stem cells.

Authors:  Teresa C Moloney; Deirdre B Hoban; Frank P Barry; Linda Howard; Eilís Dowd
Journal:  Protein Sci       Date:  2012-05-08       Impact factor: 6.725

Review 3.  Cellular responses to mild heat stress.

Authors:  H G Park; S I Han; S Y Oh; H S Kang
Journal:  Cell Mol Life Sci       Date:  2005-01       Impact factor: 9.261

4.  Heat shock improves Sca-1+ stem cell survival and directs ischemic cardiomyocytes toward a prosurvival phenotype via exosomal transfer: a critical role for HSF1/miR-34a/HSP70 pathway.

Authors:  Yuliang Feng; Wei Huang; Wei Meng; Anil G Jegga; Yigang Wang; Wenfeng Cai; Ha Won Kim; Zeeshan Pasha; Zhili Wen; Fang Rao; Rohan M Modi; Xiyong Yu; Muhammad Ashraf
Journal:  Stem Cells       Date:  2014-02       Impact factor: 6.277

5.  Cardiopoietry in motion: primed mesenchymal stem cells for ischemic cardiomyopathy.

Authors:  Charles E Murry; Nathan J Palpant; W Robb MacLellan
Journal:  J Am Coll Cardiol       Date:  2013-04-10       Impact factor: 24.094

6.  Heat-shock protein 70 antagonizes apoptosis-inducing factor.

Authors:  L Ravagnan; S Gurbuxani; S A Susin; C Maisse; E Daugas; N Zamzami; T Mak; M Jäättelä; J M Penninger; C Garrido; G Kroemer
Journal:  Nat Cell Biol       Date:  2001-09       Impact factor: 28.824

7.  Guidelines for the use and interpretation of assays for monitoring autophagy.

Authors:  Daniel J Klionsky; Fabio C Abdalla; Hagai Abeliovich; Robert T Abraham; Abraham Acevedo-Arozena; Khosrow Adeli; Lotta Agholme; Maria Agnello; Patrizia Agostinis; Julio A Aguirre-Ghiso; Hyung Jun Ahn; Ouardia Ait-Mohamed; Slimane Ait-Si-Ali; Takahiko Akematsu; Shizuo Akira; Hesham M Al-Younes; Munir A Al-Zeer; Matthew L Albert; Roger L Albin; Javier Alegre-Abarrategui; Maria Francesca Aleo; Mehrdad Alirezaei; Alexandru Almasan; Maylin Almonte-Becerril; Atsuo Amano; Ravi Amaravadi; Shoba Amarnath; Amal O Amer; Nathalie Andrieu-Abadie; Vellareddy Anantharam; David K Ann; Shailendra Anoopkumar-Dukie; Hiroshi Aoki; Nadezda Apostolova; Giuseppe Arancia; John P Aris; Katsuhiko Asanuma; Nana Y O Asare; Hisashi Ashida; Valerie Askanas; David S Askew; Patrick Auberger; Misuzu Baba; Steven K Backues; Eric H Baehrecke; Ben A Bahr; Xue-Yuan Bai; Yannick Bailly; Robert Baiocchi; Giulia Baldini; Walter Balduini; Andrea Ballabio; Bruce A Bamber; Edward T W Bampton; Gábor Bánhegyi; Clinton R Bartholomew; Diane C Bassham; Robert C Bast; Henri Batoko; Boon-Huat Bay; Isabelle Beau; Daniel M Béchet; Thomas J Begley; Christian Behl; Christian Behrends; Soumeya Bekri; Bryan Bellaire; Linda J Bendall; Luca Benetti; Laura Berliocchi; Henri Bernardi; Francesca Bernassola; Sébastien Besteiro; Ingrid Bhatia-Kissova; Xiaoning Bi; Martine Biard-Piechaczyk; Janice S Blum; Lawrence H Boise; Paolo Bonaldo; David L Boone; Beat C Bornhauser; Karina R Bortoluci; Ioannis Bossis; Frédéric Bost; Jean-Pierre Bourquin; Patricia Boya; Michaël Boyer-Guittaut; Peter V Bozhkov; Nathan R Brady; Claudio Brancolini; Andreas Brech; Jay E Brenman; Ana Brennand; Emery H Bresnick; Patrick Brest; Dave Bridges; Molly L Bristol; Paul S Brookes; Eric J Brown; John H Brumell; Nicola Brunetti-Pierri; Ulf T Brunk; Dennis E Bulman; Scott J Bultman; Geert Bultynck; Lena F Burbulla; Wilfried Bursch; Jonathan P Butchar; Wanda Buzgariu; Sergio P Bydlowski; Ken Cadwell; Monika Cahová; Dongsheng Cai; Jiyang Cai; Qian Cai; Bruno Calabretta; Javier Calvo-Garrido; Nadine Camougrand; Michelangelo Campanella; Jenny Campos-Salinas; Eleonora Candi; Lizhi Cao; Allan B Caplan; Simon R Carding; Sandra M Cardoso; Jennifer S Carew; Cathleen R Carlin; Virginie Carmignac; Leticia A M Carneiro; Serena Carra; Rosario A Caruso; Giorgio Casari; Caty Casas; Roberta Castino; Eduardo Cebollero; Francesco Cecconi; Jean Celli; Hassan Chaachouay; Han-Jung Chae; Chee-Yin Chai; David C Chan; Edmond Y Chan; Raymond Chuen-Chung Chang; Chi-Ming Che; Ching-Chow Chen; Guang-Chao Chen; Guo-Qiang Chen; Min Chen; Quan Chen; Steve S-L Chen; WenLi Chen; Xi Chen; Xiangmei Chen; Xiequn Chen; Ye-Guang Chen; Yingyu Chen; Yongqiang Chen; Yu-Jen Chen; Zhixiang Chen; Alan Cheng; Christopher H K Cheng; Yan Cheng; Heesun Cheong; Jae-Ho Cheong; Sara Cherry; Russ Chess-Williams; Zelda H Cheung; Eric Chevet; Hui-Ling Chiang; Roberto Chiarelli; Tomoki Chiba; Lih-Shen Chin; Shih-Hwa Chiou; Francis V Chisari; Chi Hin Cho; Dong-Hyung Cho; Augustine M K Choi; DooSeok Choi; Kyeong Sook Choi; Mary E Choi; Salem Chouaib; Divaker Choubey; Vinay Choubey; Charleen T Chu; Tsung-Hsien Chuang; Sheau-Huei Chueh; Taehoon Chun; Yong-Joon Chwae; Mee-Len Chye; Roberto Ciarcia; Maria R Ciriolo; Michael J Clague; Robert S B Clark; Peter G H Clarke; Robert Clarke; Patrice Codogno; Hilary A Coller; María I Colombo; Sergio Comincini; Maria Condello; Fabrizio Condorelli; Mark R Cookson; Graham H Coombs; Isabelle Coppens; Ramon Corbalan; Pascale Cossart; Paola Costelli; Safia Costes; Ana Coto-Montes; Eduardo Couve; Fraser P Coxon; James M Cregg; José L Crespo; Marianne J Cronjé; Ana Maria Cuervo; Joseph J Cullen; Mark J Czaja; Marcello D'Amelio; Arlette Darfeuille-Michaud; Lester M Davids; Faith E Davies; Massimo De Felici; John F de Groot; Cornelis A M de Haan; Luisa De Martino; Angelo De Milito; Vincenzo De Tata; Jayanta Debnath; Alexei Degterev; Benjamin Dehay; Lea M D Delbridge; Francesca Demarchi; Yi Zhen Deng; Jörn Dengjel; Paul Dent; Donna Denton; Vojo Deretic; Shyamal D Desai; Rodney J Devenish; Mario Di Gioacchino; Gilbert Di Paolo; Chiara Di Pietro; Guillermo Díaz-Araya; Inés Díaz-Laviada; Maria T Diaz-Meco; Javier Diaz-Nido; Ivan Dikic; Savithramma P Dinesh-Kumar; Wen-Xing Ding; Clark W Distelhorst; Abhinav Diwan; Mojgan Djavaheri-Mergny; Svetlana Dokudovskaya; Zheng Dong; Frank C Dorsey; Victor Dosenko; James J Dowling; Stephen Doxsey; Marlène Dreux; Mark E Drew; Qiuhong Duan; Michel A Duchosal; Karen Duff; Isabelle Dugail; Madeleine Durbeej; Michael Duszenko; Charles L Edelstein; Aimee L Edinger; Gustavo Egea; Ludwig Eichinger; N Tony Eissa; Suhendan Ekmekcioglu; Wafik S El-Deiry; Zvulun Elazar; Mohamed Elgendy; Lisa M Ellerby; Kai Er Eng; Anna-Mart Engelbrecht; Simone Engelender; Jekaterina Erenpreisa; Ricardo Escalante; Audrey Esclatine; Eeva-Liisa Eskelinen; Lucile Espert; Virginia Espina; Huizhou Fan; Jia Fan; Qi-Wen Fan; Zhen Fan; Shengyun Fang; Yongqi Fang; Manolis Fanto; Alessandro Fanzani; Thomas Farkas; Jean-Claude Farré; Mathias Faure; Marcus Fechheimer; Carl G Feng; Jian Feng; Qili Feng; Youji Feng; László Fésüs; Ralph Feuer; Maria E Figueiredo-Pereira; Gian Maria Fimia; Diane C Fingar; Steven Finkbeiner; Toren Finkel; Kim D Finley; Filomena Fiorito; Edward A Fisher; Paul B Fisher; Marc Flajolet; Maria L Florez-McClure; Salvatore Florio; Edward A Fon; Francesco Fornai; Franco Fortunato; Rati Fotedar; Daniel H Fowler; Howard S Fox; Rodrigo Franco; Lisa B Frankel; Marc Fransen; José M Fuentes; Juan Fueyo; Jun Fujii; Kozo Fujisaki; Eriko Fujita; Mitsunori Fukuda; Ruth H Furukawa; Matthias Gaestel; Philippe Gailly; Malgorzata Gajewska; Brigitte Galliot; Vincent Galy; Subramaniam Ganesh; Barry Ganetzky; Ian G Ganley; Fen-Biao Gao; George F Gao; Jinming Gao; Lorena Garcia; Guillermo Garcia-Manero; Mikel Garcia-Marcos; Marjan Garmyn; Andrei L Gartel; Evelina Gatti; Mathias Gautel; Thomas R Gawriluk; Matthew E Gegg; Jiefei Geng; Marc Germain; Jason E Gestwicki; David A Gewirtz; Saeid Ghavami; Pradipta Ghosh; Anna M Giammarioli; Alexandra N Giatromanolaki; Spencer B Gibson; Robert W Gilkerson; Michael L Ginger; Henry N Ginsberg; Jakub Golab; Michael S Goligorsky; Pierre Golstein; Candelaria Gomez-Manzano; Ebru Goncu; Céline Gongora; Claudio D Gonzalez; Ramon Gonzalez; Cristina González-Estévez; Rosa Ana González-Polo; Elena Gonzalez-Rey; Nikolai V Gorbunov; Sharon Gorski; Sandro Goruppi; Roberta A Gottlieb; Devrim Gozuacik; Giovanna Elvira Granato; Gary D Grant; Kim N Green; Aleš Gregorc; Frédéric Gros; Charles Grose; Thomas W Grunt; Philippe Gual; Jun-Lin Guan; Kun-Liang Guan; Sylvie M Guichard; Anna S Gukovskaya; Ilya Gukovsky; Jan Gunst; Asa B Gustafsson; Andrew J Halayko; Amber N Hale; Sandra K Halonen; Maho Hamasaki; Feng Han; Ting Han; Michael K Hancock; Malene Hansen; Hisashi Harada; Masaru Harada; Stefan E Hardt; J Wade Harper; Adrian L Harris; James Harris; Steven D Harris; Makoto Hashimoto; Jeffrey A Haspel; Shin-ichiro Hayashi; Lori A Hazelhurst; Congcong He; You-Wen He; Marie-Joseé Hébert; Kim A Heidenreich; Miep H Helfrich; Gudmundur V Helgason; Elizabeth P Henske; Brian Herman; Paul K Herman; Claudio Hetz; Sabine Hilfiker; Joseph A Hill; Lynne J Hocking; Paul Hofman; Thomas G Hofmann; Jörg Höhfeld; Tessa L Holyoake; Ming-Huang Hong; David A Hood; Gökhan S Hotamisligil; Ewout J Houwerzijl; Maria Høyer-Hansen; Bingren Hu; Chien-An A Hu; Hong-Ming Hu; Ya Hua; Canhua Huang; Ju Huang; Shengbing Huang; Wei-Pang Huang; Tobias B Huber; Won-Ki Huh; Tai-Ho Hung; Ted R Hupp; Gang Min Hur; James B Hurley; Sabah N A Hussain; Patrick J Hussey; Jung Jin Hwang; Seungmin Hwang; Atsuhiro Ichihara; Shirin Ilkhanizadeh; Ken Inoki; Takeshi Into; Valentina Iovane; Juan L Iovanna; Nancy Y Ip; Yoshitaka Isaka; Hiroyuki Ishida; Ciro Isidoro; Ken-ichi Isobe; Akiko Iwasaki; Marta Izquierdo; Yotaro Izumi; Panu M Jaakkola; Marja Jäättelä; George R Jackson; William T Jackson; Bassam Janji; Marina Jendrach; Ju-Hong Jeon; Eui-Bae Jeung; Hong Jiang; Hongchi Jiang; Jean X Jiang; Ming Jiang; Qing Jiang; Xuejun Jiang; Xuejun Jiang; Alberto Jiménez; Meiyan Jin; Shengkan Jin; Cheol O Joe; Terje Johansen; Daniel E Johnson; Gail V W Johnson; Nicola L Jones; Bertrand Joseph; Suresh K Joseph; Annie M Joubert; Gábor Juhász; Lucienne Juillerat-Jeanneret; Chang Hwa Jung; Yong-Keun Jung; Kai Kaarniranta; Allen Kaasik; Tomohiro Kabuta; Motoni Kadowaki; Katarina Kagedal; Yoshiaki Kamada; Vitaliy O Kaminskyy; Harm H Kampinga; Hiromitsu Kanamori; Chanhee Kang; Khong Bee Kang; Kwang Il Kang; Rui Kang; Yoon-A Kang; Tomotake Kanki; Thirumala-Devi Kanneganti; Haruo Kanno; Anumantha G Kanthasamy; Arthi Kanthasamy; Vassiliki Karantza; Gur P Kaushal; Susmita Kaushik; Yoshinori Kawazoe; Po-Yuan Ke; John H Kehrl; Ameeta Kelekar; Claus Kerkhoff; David H Kessel; Hany Khalil; Jan A K W Kiel; Amy A Kiger; Akio Kihara; Deok Ryong Kim; Do-Hyung Kim; Dong-Hou Kim; Eun-Kyoung Kim; Hyung-Ryong Kim; Jae-Sung Kim; Jeong Hun Kim; Jin Cheon Kim; John K Kim; Peter K Kim; Seong Who Kim; Yong-Sun Kim; Yonghyun Kim; Adi Kimchi; Alec C Kimmelman; Jason S King; Timothy J Kinsella; Vladimir Kirkin; Lorrie A Kirshenbaum; Katsuhiko Kitamoto; Kaio Kitazato; Ludger Klein; Walter T Klimecki; Jochen Klucken; Erwin Knecht; Ben C B Ko; Jan C Koch; Hiroshi Koga; Jae-Young Koh; Young Ho Koh; Masato Koike; Masaaki Komatsu; Eiki Kominami; Hee Jeong Kong; Wei-Jia Kong; Viktor I Korolchuk; Yaichiro Kotake; Michael I Koukourakis; Juan B Kouri Flores; Attila L Kovács; Claudine Kraft; Dimitri Krainc; Helmut Krämer; Carole Kretz-Remy; Anna M Krichevsky; Guido Kroemer; Rejko Krüger; Oleg Krut; Nicholas T Ktistakis; Chia-Yi Kuan; Roza Kucharczyk; Ashok Kumar; Raj Kumar; Sharad Kumar; Mondira Kundu; Hsing-Jien Kung; Tino Kurz; Ho Jeong Kwon; Albert R La Spada; Frank Lafont; Trond Lamark; Jacques Landry; Jon D Lane; Pierre Lapaquette; Jocelyn F Laporte; Lajos László; Sergio Lavandero; Josée N Lavoie; Robert Layfield; Pedro A Lazo; Weidong Le; Laurent Le Cam; Daniel J Ledbetter; Alvin J X Lee; Byung-Wan Lee; Gyun Min Lee; Jongdae Lee; Ju-Hyun Lee; Michael Lee; Myung-Shik Lee; Sug Hyung Lee; Christiaan Leeuwenburgh; Patrick Legembre; Renaud Legouis; Michael Lehmann; Huan-Yao Lei; Qun-Ying Lei; David A Leib; José Leiro; John J Lemasters; Antoinette Lemoine; Maciej S Lesniak; Dina Lev; Victor V Levenson; Beth Levine; Efrat Levy; Faqiang Li; Jun-Lin Li; Lian Li; Sheng Li; Weijie Li; Xue-Jun Li; Yan-bo Li; Yi-Ping Li; Chengyu Liang; Qiangrong Liang; Yung-Feng Liao; Pawel P Liberski; Andrew Lieberman; Hyunjung J Lim; Kah-Leong Lim; Kyu Lim; Chiou-Feng Lin; Fu-Cheng Lin; Jian Lin; Jiandie D Lin; Kui Lin; Wan-Wan Lin; Weei-Chin Lin; Yi-Ling Lin; Rafael Linden; Paul Lingor; Jennifer Lippincott-Schwartz; Michael P Lisanti; Paloma B Liton; Bo Liu; Chun-Feng Liu; Kaiyu Liu; Leyuan Liu; Qiong A Liu; Wei Liu; Young-Chau Liu; Yule Liu; Richard A Lockshin; Chun-Nam Lok; Sagar Lonial; Benjamin Loos; Gabriel Lopez-Berestein; Carlos López-Otín; Laura Lossi; Michael T Lotze; Peter Lőw; Binfeng Lu; Bingwei Lu; Bo Lu; Zhen Lu; Frédéric Luciano; Nicholas W Lukacs; Anders H Lund; Melinda A Lynch-Day; Yong Ma; Fernando Macian; Jeff P MacKeigan; Kay F Macleod; Frank Madeo; Luigi Maiuri; Maria Chiara Maiuri; Davide Malagoli; May Christine V Malicdan; Walter Malorni; Na Man; Eva-Maria Mandelkow; Stéphen Manon; Irena Manov; Kai Mao; Xiang Mao; Zixu Mao; Philippe Marambaud; Daniela Marazziti; Yves L Marcel; Katie Marchbank; Piero Marchetti; Stefan J Marciniak; Mateus Marcondes; Mohsen Mardi; Gabriella Marfe; Guillermo Mariño; Maria Markaki; Mark R Marten; Seamus J Martin; Camille Martinand-Mari; Wim Martinet; Marta Martinez-Vicente; Matilde Masini; Paola Matarrese; Saburo Matsuo; Raffaele Matteoni; Andreas Mayer; Nathalie M Mazure; David J McConkey; Melanie J McConnell; Catherine McDermott; Christine McDonald; Gerald M McInerney; Sharon L McKenna; BethAnn McLaughlin; Pamela J McLean; Christopher R McMaster; G Angus McQuibban; Alfred J Meijer; Miriam H Meisler; Alicia Meléndez; Thomas J Melia; Gerry Melino; Maria A Mena; Javier A Menendez; Rubem F S Menna-Barreto; Manoj B Menon; Fiona M Menzies; Carol A Mercer; Adalberto Merighi; Diane E Merry; Stefania Meschini; Christian G Meyer; Thomas F Meyer; Chao-Yu Miao; Jun-Ying Miao; Paul A M Michels; Carine Michiels; Dalibor Mijaljica; Ana Milojkovic; Saverio Minucci; Clelia Miracco; Cindy K Miranti; Ioannis Mitroulis; Keisuke Miyazawa; Noboru Mizushima; Baharia Mograbi; Simin Mohseni; Xavier Molero; Bertrand Mollereau; Faustino Mollinedo; Takashi Momoi; Iryna Monastyrska; Martha M Monick; Mervyn J Monteiro; Michael N Moore; Rodrigo Mora; Kevin Moreau; Paula I Moreira; Yuji Moriyasu; Jorge Moscat; Serge Mostowy; Jeremy C Mottram; Tomasz Motyl; Charbel E-H Moussa; Sylke Müller; Sylviane Muller; Karl Münger; Christian Münz; Leon O Murphy; Maureen E Murphy; Antonio Musarò; Indira Mysorekar; Eiichiro Nagata; Kazuhiro Nagata; Aimable Nahimana; Usha Nair; Toshiyuki Nakagawa; Kiichi Nakahira; Hiroyasu Nakano; Hitoshi Nakatogawa; Meera Nanjundan; Naweed I Naqvi; Derek P Narendra; Masashi Narita; Miguel Navarro; Steffan T Nawrocki; Taras Y Nazarko; Andriy Nemchenko; Mihai G Netea; Thomas P Neufeld; Paul A Ney; Ioannis P Nezis; Huu Phuc Nguyen; Daotai Nie; Ichizo Nishino; Corey Nislow; Ralph A Nixon; Takeshi Noda; Angelika A Noegel; Anna Nogalska; Satoru Noguchi; Lucia Notterpek; Ivana Novak; Tomoyoshi Nozaki; Nobuyuki Nukina; Thorsten Nürnberger; Beat Nyfeler; Keisuke Obara; Terry D Oberley; Salvatore Oddo; Michinaga Ogawa; Toya Ohashi; Koji Okamoto; Nancy L Oleinick; F Javier Oliver; Laura J Olsen; Stefan Olsson; Onya Opota; Timothy F Osborne; Gary K Ostrander; Kinya Otsu; Jing-hsiung James Ou; Mireille Ouimet; Michael Overholtzer; Bulent Ozpolat; Paolo Paganetti; Ugo Pagnini; Nicolas Pallet; Glen E Palmer; Camilla Palumbo; Tianhong Pan; Theocharis Panaretakis; Udai Bhan Pandey; Zuzana Papackova; Issidora Papassideri; Irmgard Paris; Junsoo Park; Ohkmae K Park; Jan B Parys; Katherine R Parzych; Susann Patschan; Cam Patterson; Sophie Pattingre; John M Pawelek; Jianxin Peng; David H Perlmutter; Ida Perrotta; George Perry; Shazib Pervaiz; Matthias Peter; Godefridus J Peters; Morten Petersen; Goran Petrovski; James M Phang; Mauro Piacentini; Philippe Pierre; Valérie Pierrefite-Carle; Gérard Pierron; Ronit Pinkas-Kramarski; Antonio Piras; Natik Piri; Leonidas C Platanias; Stefanie Pöggeler; Marc Poirot; Angelo Poletti; Christian Poüs; Mercedes Pozuelo-Rubio; Mette Prætorius-Ibba; Anil Prasad; Mark Prescott; Muriel Priault; Nathalie Produit-Zengaffinen; Ann Progulske-Fox; Tassula Proikas-Cezanne; Serge Przedborski; Karin Przyklenk; Rosa Puertollano; Julien Puyal; Shu-Bing Qian; Liang Qin; Zheng-Hong Qin; Susan E Quaggin; Nina Raben; Hannah Rabinowich; Simon W Rabkin; Irfan Rahman; Abdelhaq Rami; Georg Ramm; Glenn Randall; Felix Randow; V Ashutosh Rao; Jeffrey C Rathmell; Brinda Ravikumar; Swapan K Ray; Bruce H Reed; John C Reed; Fulvio Reggiori; Anne Régnier-Vigouroux; Andreas S Reichert; John J Reiners; Russel J Reiter; Jun Ren; José L Revuelta; Christopher J Rhodes; Konstantinos Ritis; Elizete Rizzo; Jeffrey Robbins; Michel Roberge; Hernan Roca; Maria C Roccheri; Stephane Rocchi; H Peter Rodemann; Santiago Rodríguez de Córdoba; Bärbel Rohrer; Igor B Roninson; Kirill Rosen; Magdalena M Rost-Roszkowska; Mustapha Rouis; Kasper M A Rouschop; Francesca Rovetta; Brian P Rubin; David C Rubinsztein; Klaus Ruckdeschel; Edmund B Rucker; Assaf Rudich; Emil Rudolf; Nelson Ruiz-Opazo; Rossella Russo; Tor Erik Rusten; Kevin M Ryan; Stefan W Ryter; David M Sabatini; Junichi Sadoshima; Tapas Saha; Tatsuya Saitoh; Hiroshi Sakagami; Yasuyoshi Sakai; Ghasem Hoseini Salekdeh; Paolo Salomoni; Paul M Salvaterra; Guy Salvesen; Rosa Salvioli; Anthony M J Sanchez; José A Sánchez-Alcázar; Ricardo Sánchez-Prieto; Marco Sandri; Uma Sankar; Poonam Sansanwal; Laura Santambrogio; Shweta Saran; Sovan Sarkar; Minnie Sarwal; Chihiro Sasakawa; Ausra Sasnauskiene; Miklós Sass; Ken Sato; Miyuki Sato; Anthony H V Schapira; Michael Scharl; Hermann M Schätzl; Wiep Scheper; Stefano Schiaffino; Claudio Schneider; Marion E Schneider; Regine Schneider-Stock; Patricia V Schoenlein; Daniel F Schorderet; Christoph Schüller; Gary K Schwartz; Luca Scorrano; Linda Sealy; Per O Seglen; Juan Segura-Aguilar; Iban Seiliez; Oleksandr Seleverstov; Christian Sell; Jong Bok Seo; Duska Separovic; Vijayasaradhi Setaluri; Takao Setoguchi; Carmine Settembre; John J Shacka; Mala Shanmugam; Irving M Shapiro; Eitan Shaulian; Reuben J Shaw; James H Shelhamer; Han-Ming Shen; Wei-Chiang Shen; Zu-Hang Sheng; Yang Shi; Kenichi Shibuya; Yoshihiro Shidoji; Jeng-Jer Shieh; Chwen-Ming Shih; Yohta Shimada; Shigeomi Shimizu; Takahiro Shintani; Orian S Shirihai; Gordon C Shore; Andriy A Sibirny; Stan B Sidhu; Beata Sikorska; Elaine C M Silva-Zacarin; Alison Simmons; Anna Katharina Simon; Hans-Uwe Simon; Cristiano Simone; Anne Simonsen; David A Sinclair; Rajat Singh; Debasish Sinha; Frank A Sinicrope; Agnieszka Sirko; Parco M Siu; Efthimios Sivridis; Vojtech Skop; Vladimir P Skulachev; Ruth S Slack; Soraya S Smaili; Duncan R Smith; Maria S Soengas; Thierry Soldati; Xueqin Song; Anil K Sood; Tuck Wah Soong; Federica Sotgia; Stephen A Spector; Claudia D Spies; Wolfdieter Springer; Srinivasa M Srinivasula; Leonidas Stefanis; Joan S Steffan; Ruediger Stendel; Harald Stenmark; Anastasis Stephanou; Stephan T Stern; Cinthya Sternberg; Björn Stork; Peter Strålfors; Carlos S Subauste; Xinbing Sui; David Sulzer; Jiaren Sun; Shi-Yong Sun; Zhi-Jun Sun; Joseph J Y Sung; Kuninori Suzuki; Toshihiko Suzuki; Michele S Swanson; Charles Swanton; Sean T Sweeney; Lai-King Sy; Gyorgy Szabadkai; Ira Tabas; Heinrich Taegtmeyer; Marco Tafani; Krisztina Takács-Vellai; Yoshitaka Takano; Kaoru Takegawa; Genzou Takemura; Fumihiko Takeshita; Nicholas J Talbot; Kevin S W Tan; Keiji Tanaka; Kozo Tanaka; Daolin Tang; Dingzhong Tang; Isei Tanida; Bakhos A Tannous; Nektarios Tavernarakis; Graham S Taylor; Gregory A Taylor; J Paul Taylor; Lance S Terada; Alexei Terman; Gianluca Tettamanti; Karin Thevissen; Craig B Thompson; Andrew Thorburn; Michael Thumm; FengFeng Tian; Yuan Tian; Glauco Tocchini-Valentini; Aviva M Tolkovsky; Yasuhiko Tomino; Lars Tönges; Sharon A Tooze; Cathy Tournier; John Tower; Roberto Towns; Vladimir Trajkovic; Leonardo H Travassos; Ting-Fen Tsai; Mario P Tschan; Takeshi Tsubata; Allan Tsung; Boris Turk; Lorianne S Turner; Suresh C Tyagi; Yasuo Uchiyama; Takashi Ueno; Midori Umekawa; Rika Umemiya-Shirafuji; Vivek K Unni; Maria I Vaccaro; Enza Maria Valente; Greet Van den Berghe; Ida J van der Klei; Wouter van Doorn; Linda F van Dyk; Marjolein van Egmond; Leo A van Grunsven; Peter Vandenabeele; Wim P Vandenberghe; Ilse Vanhorebeek; Eva C Vaquero; Guillermo Velasco; Tibor Vellai; Jose Miguel Vicencio; Richard D Vierstra; Miquel Vila; Cécile Vindis; Giampietro Viola; Maria Teresa Viscomi; Olga V Voitsekhovskaja; Clarissa von Haefen; Marcela Votruba; Keiji Wada; Richard Wade-Martins; Cheryl L Walker; Craig M Walsh; Jochen Walter; Xiang-Bo Wan; Aimin Wang; Chenguang Wang; Dawei Wang; Fan Wang; Fen Wang; Guanghui Wang; Haichao Wang; Hong-Gang Wang; Horng-Dar Wang; Jin Wang; Ke Wang; Mei Wang; Richard C Wang; Xinglong Wang; Xuejun Wang; Ying-Jan Wang; Yipeng Wang; Zhen Wang; Zhigang Charles Wang; Zhinong Wang; Derick G Wansink; Diane M Ward; Hirotaka Watada; Sarah L Waters; Paul Webster; Lixin Wei; Conrad C Weihl; William A Weiss; Scott M Welford; Long-Ping Wen; Caroline A Whitehouse; J Lindsay Whitton; Alexander J Whitworth; Tom Wileman; John W Wiley; Simon Wilkinson; Dieter Willbold; Roger L Williams; Peter R Williamson; Bradly G Wouters; Chenghan Wu; Dao-Cheng Wu; William K K Wu; Andreas Wyttenbach; Ramnik J Xavier; Zhijun Xi; Pu Xia; Gengfu Xiao; Zhiping Xie; Zhonglin Xie; Da-zhi Xu; Jianzhen Xu; Liang Xu; Xiaolei Xu; Ai Yamamoto; Akitsugu Yamamoto; Shunhei Yamashina; Michiaki Yamashita; Xianghua Yan; Mitsuhiro Yanagida; Dun-Sheng Yang; Elizabeth Yang; Jin-Ming Yang; Shi Yu Yang; Wannian Yang; Wei Yuan Yang; Zhifen Yang; Meng-Chao Yao; Tso-Pang Yao; Behzad Yeganeh; Wei-Lien Yen; Jia-jing Yin; Xiao-Ming Yin; Ook-Joon Yoo; Gyesoon Yoon; Seung-Yong Yoon; Tomohiro Yorimitsu; Yuko Yoshikawa; Tamotsu Yoshimori; Kohki Yoshimoto; Ho Jin You; Richard J Youle; Anas Younes; Li Yu; Long Yu; Seong-Woon Yu; Wai Haung Yu; Zhi-Min Yuan; Zhenyu Yue; Cheol-Heui Yun; Michisuke Yuzaki; Olga Zabirnyk; Elaine Silva-Zacarin; David Zacks; Eldad Zacksenhaus; Nadia Zaffaroni; Zahra Zakeri; Herbert J Zeh; Scott O Zeitlin; Hong Zhang; Hui-Ling Zhang; Jianhua Zhang; Jing-Pu Zhang; Lin Zhang; Long Zhang; Ming-Yong Zhang; Xu Dong Zhang; Mantong Zhao; Yi-Fang Zhao; Ying Zhao; Zhizhuang J Zhao; Xiaoxiang Zheng; Boris Zhivotovsky; Qing Zhong; Cong-Zhao Zhou; Changlian Zhu; Wei-Guo Zhu; Xiao-Feng Zhu; Xiongwei Zhu; Yuangang Zhu; Teresa Zoladek; Wei-Xing Zong; Antonio Zorzano; Jürgen Zschocke; Brian Zuckerbraun
Journal:  Autophagy       Date:  2012-04       Impact factor: 16.016

Review 8.  Preconditioning stem cells for in vivo delivery.

Authors:  Sébastien Sart; Teng Ma; Yan Li
Journal:  Biores Open Access       Date:  2014-08-01

9.  Effect of stem cell transplantation of premature ovarian failure in animal models and patients: A meta-analysis and case report.

Authors:  Lei Chen; Shilei Guo; Cui Wei; Honglan Li; Haiya Wang; Yan Xu
Journal:  Exp Ther Med       Date:  2018-03-20       Impact factor: 2.447

10.  Heat shock pretreatment of mesenchymal stem cells for inhibiting the apoptosis of ovarian granulosa cells enhanced the repair effect on chemotherapy-induced premature ovarian failure.

Authors:  Xiaoying Chen; Qing Wang; Xinran Li; Qingru Wang; Jiaxin Xie; Xiafei Fu
Journal:  Stem Cell Res Ther       Date:  2018-09-26       Impact factor: 6.832

View more
  11 in total

1.  NUMB facilitates autophagy initiation through targeting SCFβ-TrCP2 complex.

Authors:  Hao Li; Shuangshuang Shu; Miaomiao Zhou; Ying Chen; An Xiao; Yuanyuan Ma; Fengxin Zhu; Zheng Hu; Jing Nie
Journal:  Cell Death Differ       Date:  2022-01-11       Impact factor: 12.067

2.  Heat shock preconditioning mesenchymal stem cells attenuate acute lung injury via reducing NLRP3 inflammasome activation in macrophages.

Authors:  Haijin Lv; Xiaofeng Yuan; Jiebin Zhang; Tongyu Lu; Jia Yao; Jun Zheng; Jianye Cai; Jiaqi Xiao; Haitian Chen; Shujuan Xie; Ying Ruan; Yuling An; Xin Sui; Huimin Yi
Journal:  Stem Cell Res Ther       Date:  2021-05-17       Impact factor: 8.079

3.  Transplanted Erythropoietin-Expressing Mesenchymal Stem Cells Promote Pro-survival Gene Expression and Protect Photoreceptors From Sodium Iodate-Induced Cytotoxicity in a Retinal Degeneration Model.

Authors:  Avin Ee-Hwan Koh; Hiba Amer Alsaeedi; Munirah Binti Abd Rashid; Chenshen Lam; Mohd Hairul Nizam Harun; Min Hwei Ng; Hazlita Mohd Isa; Kong Yong Then; Mae-Lynn Catherine Bastion; Aisha Farhana; Mohammad Khursheed Alam; Suresh Kumar Subbiah; Pooi Ling Mok
Journal:  Front Cell Dev Biol       Date:  2021-04-27

4.  6-gingerol protects nucleus pulposus-derived mesenchymal stem cells from oxidative injury by activating autophagy.

Authors:  Li-Ping Nan; Feng Wang; Yang Liu; Zhong Wu; Xin-Min Feng; Jun-Jian Liu; Liang Zhang
Journal:  World J Stem Cells       Date:  2020-12-26       Impact factor: 5.326

5.  Synergistic stimulation of surface topography and biphasic electric current promotes muscle regeneration.

Authors:  Indong Jun; Na Li; Jaehee Shin; Jaeho Park; Young Jun Kim; Hojeong Jeon; Hyuk Choi; Jae-Gu Cho; Byoung Chan Choi; Hyung-Seop Han; Jae-Jun Song
Journal:  Bioact Mater       Date:  2021-10-19

6.  High-Intensity Focused Ultrasound Induces Adipogenesis via Control of Cilia in Adipose-Derived Stem Cells in Subcutaneous Adipose Tissue.

Authors:  Seyeon Oh; Hyoung Moon Kim; Sosorburam Batsukh; Hye Jin Sun; Taehui Kim; Donghwan Kang; Kuk Hui Son; Kyunghee Byun
Journal:  Int J Mol Sci       Date:  2022-08-09       Impact factor: 6.208

7.  Effect of Heat Shock Preconditioning on Pressure Injury Prevention via Hsp27 Upregulation in Rat Models.

Authors:  Huiwen Xu; En Takashi; Jingyan Liang; Yajie Chen; Yuan Yuan; Jianglin Fan
Journal:  Int J Mol Sci       Date:  2022-08-11       Impact factor: 6.208

8.  Trametenolic Acid B Triggers HSP90AA4P and Autophagy in HepG2/2.2.15 Cells by Proteomic Analysis.

Authors:  Feifan Shi; Yihe Fu; Junzhi Wang; Lie Li; Ailing Wang; Yuan Yuan; Huajun Luo; Haibo He; Gaigai Deng
Journal:  ACS Omega       Date:  2020-05-26

Review 9.  Protein quality control of cell stemness.

Authors:  Pengze Yan; Jie Ren; Weiqi Zhang; Jing Qu; Guang-Hui Liu
Journal:  Cell Regen       Date:  2020-11-12

Review 10.  Role of Extracellular Vesicles in Compromising Cellular Resilience to Environmental Stressors.

Authors:  Mona G Alharbi; Seok Hee Lee; Aaser M Abdelazim; Islam M Saadeldin; Mosleh M Abomughaid
Journal:  Biomed Res Int       Date:  2021-07-20       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.